A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel) in the Treatment of Subjects With Vascular Injury Resulting From Arteriovenous Graft Surgery for Hemodialysis Access
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2016
Price : $35 *
At a glance
- Drugs SRM 003 (Primary)
- Indications Peripheral vascular disorders
- Focus Therapeutic Use
- Sponsors Shire
- 30 Dec 2015 Status changed from completed to discontinued, as reported by ClinicalTrials.gov record.
- 04 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Sep 2014 Planned End Date changed from 1 Sep 2015 to 1 Apr 2015, as reported by ClinicalTrials.gov record.